Lyme Disease Testing Market Analysis Highlights Growth To $16.46 Billion By 2030 At 9% CAGR

Understanding the future of Lyme disease testing reveals promising growth and innovation on the horizon. As diagnostic technologies advance and new testing approaches emerge, the market is set to expand significantly, driven by a range of factors including smarter diagnostics and broader accessibility. Here's an in-depth overview of the Lyme disease testing market, its major players, prevailing trends, and segmentation.

Projected Growth Trajectory of the Lyme Disease Testing Market
The Lyme disease testing market is anticipated to experience substantial expansion, reaching a valuation of $16.46 billion by 2030. This growth reflects a compound annual growth rate (CAGR) of 9.0%. Factors fueling this upward trend include the increasing use of AI-assisted diagnostic methods, the rising popularity of home-testing kits, the broadening of multi-disease test panels, enhanced government funding directed toward tick-borne disease monitoring, and the adoption of cloud-based laboratory data management systems. Key trends expected to influence the market during this period are the expansion of point-of-care testing, broader availability of home-based Lyme disease diagnostics, the development of multi-pathogen tick panels, the uptake of rapid test kits, and more personalized diagnostic protocols.

Download a free sample of the lyme disease testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Major Companies Leading the Lyme Disease Testing Sector
Several prominent companies shape the competitive landscape of the Lyme disease testing industry. These include Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., and Seegene Inc.

Collaborative Efforts to Enhance Lyme Disease Diagnostics
In May 2024, T2 Biosystems Inc., a U.S.-based in vitro diagnostics company, joined forces with ECO Laboratory to improve Lyme disease diagnostic capabilities. This partnership focuses on advancing the development and clinical validation of the T2Lyme Panel, a molecular diagnostic tool designed for early and accurate Lyme disease detection. Leveraging ECO Laboratory's CLIA-certified infrastructure, the collaboration aims to broaden access to cutting-edge tick-borne disease testing throughout the United States. ECO Laboratory specializes in diagnostics related to Lyme and other tick-borne illnesses, making it a strategic partner in this endeavor.

View the full lyme disease testing market report:
https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Technological Innovation Driving Lyme Disease Testing Improvements
Leading companies in the Lyme disease testing market are prioritizing technological enhancements to improve test precision, shorten turnaround times, and enable earlier detection. Diagnostic tools encompass medical devices and kits that identify Lyme disease by detecting antibodies, antigens, or genetic material linked to Borrelia burgdorferi bacteria. For example, in August 2024, UK-based biotech firm EpitogenX Ltd. launched an advanced Lyme Disease Diagnostic Kit. This ELISA-based assay utilizes their proprietary EpitoGen platform, featuring approximately 120 unique Borrelia epitopes. It offers high specificity and sensitivity, supports early and strain-specific identification, and is designed for research use and diagnostic labs. This innovation aims to enhance detection accuracy and deepen understanding of Lyme disease.

Detailed Segmentation of the Global Lyme Disease Testing Market
The Lyme disease testing market is categorized by several key dimensions:

1) Test Type:
- Serological Tests
- Nucleic Acid Tests
- Urine Antigen Tests
- Other Test Types

2) Testing Methodology:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot
- Polymerase Chain Reaction (PCR)
- Immunofluorescence Assay (IFA)
- Other Emerging Technologies

3) Disease Stage:
- Early Lyme Disease
- Disseminated Lyme Disease
- Chronic Lyme Disease
- Asymptomatic Lyme Disease Detection

4) Sample Type:
- Blood
- Urine
- Cerebrospinal Fluid (CSF)
- Other Blood Samples

5) End-User:
- Hospitals and Clinics
- Diagnostic Laboratories
- Home Care Settings
- Research Institutions
- Public Health Organizations

Further subcategories break down as follows:

- Serological Tests include ELISA, Western Blot, Immunofluorescence Assay, and Line Immunoassay.
- Nucleic Acid Tests comprise Polymerase Chain Reaction, Loop-Mediated Isothermal Amplification, and Next-Generation Sequencing.
- Urine Antigen Tests feature Lateral Flow Assay, Enzyme Immunoassay, and Immunoblot urine tests.
- Other Test Types cover culture-based diagnostics, tick-borne co-infection panels, and AI-assisted diagnostic tools.

This comprehensive segmentation provides a clear framework for understanding the diverse testing approaches and markets served within the Lyme disease diagnostics landscape.

Our 2026 market reports now offer broader strategic coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.